Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-11 5:50 pm Unchanged | 13G | CREATIVE MED TECHNOLOGY HLDGS CELZ | L1 Capital Global Opportunities Master Fund Ltd. | 327,458 4.9% | 0 (Unchanged) | View |
| 2022-02-11 5:49 pm Sale | 13G | Lexaria Bioscience Corp. LEXX | L1 Capital Global Opportunities Master Fund Ltd. | 159,000 2.6% | -126,714 (-44.35%) | View |
| 2022-02-11 5:49 pm Sale | 13G | SEANERGY MARITIME HOLDINGS COR SHIP | L1 Capital Global Opportunities Master Fund Ltd. | 250,000 0.001% | -7,250,000 (-96.67%) | View |
| 2022-02-11 5:48 pm Sale | 13G | TITAN PHARMACEUTICALS INC DEL TTNP | L1 Capital Global Opportunities Master Fund Ltd. | 494,716 4.99% | -186,534 (-27.38%) | View |
| 2022-02-11 5:48 pm Sale | 13G | GEOVAX LABS INC PAR $0.001 GOVX | L1 Capital Global Opportunities Master Fund Ltd. | 0 0% | -383,948 (Position Closed) | View |
| 2022-02-11 5:47 pm Sale | 13G | BriaCell Therapeutics Corp. BCTX | L1 Capital Global Opportunities Master Fund Ltd. | 105,000 11% | -895,000 (-89.50%) | View |
| 2021-12-08 5:00 pm Purchase | 13G | CREATIVE MED TECHNOLOGY HLDGS CELZ | L1 Capital Global Opportunities Master Fund Ltd. | 327,458 5.1% | 327,458 (New Position) | View |
| 2021-11-18 4:30 pm Purchase | 13G | RECRUITER COM GROUP INC NE RCRT | L1 Capital Global Opportunities Master Fund Ltd. | 1,052,922 7.3% | 1,052,922 (New Position) | View |
| 2021-03-05 4:13 pm Purchase | 13G | BriaCell Therapeutics Corp. BCTX | L1 Capital Global Opportunities Master Fund Ltd. | 1,000,000 16.3% | 1,000,000 (New Position) | View |
| 2021-02-09 4:46 pm Sale | 13G | INVIVO THERAPEUTICS HLDGS CORP NVIVQ | L1 Capital Global Opportunities Master Fund Ltd. | 1,061,250 4.8% | -1,061,250 (-50.00%) | View |
| 2021-02-09 4:45 pm Purchase | 13G | RECON TECHNOLOGY, LTD. CLASS A RCON | L1 Capital Global Opportunities Master Fund Ltd. | 220,000 3% | 30,000 (+15.79%) | View |
| 2021-02-09 4:44 pm Sale | 13G | BIT BRO LTD 2 BETSF | L1 Capital Global Opportunities Master Fund Ltd. | 0 0% | -6,250,000 (Position Closed) | View |
| 2021-02-09 4:43 pm Sale | 13G | GLOBUS MARITIME LIMITED COM PA GLBS | L1 Capital Global Opportunities Master Fund Ltd. | 158,500 4.8% | -1,876,618 (-92.21%) | View |
| 2021-02-09 4:08 pm Sale | 13G | LM FUNDING AMERICA INC. LMFA | L1 Capital Global Opportunities Master Fund Ltd. | 955,000 3.5% | -613,000 (-39.09%) | View |
| 2021-01-25 08:26 am Sale | 13G | TITAN PHARMACEUTICALS INC DEL TTNP | L1 Capital Global Opportunities Master Fund Ltd. | 681,250 6.9% | -9,038,750 (-92.99%) | View |
| 2021-01-20 4:05 pm Purchase | 13G | Lexaria Bioscience Corp. LEXX | L1 Capital Global Opportunities Master Fund Ltd. | 285,714 5.6% | 285,714 (New Position) | View |
| 2021-01-19 08:31 am Purchase | 13G | AMERICAN INTERNATIONAL HOLDINGS CORP. AMIH | L1 Capital Global Opportunities Master Fund Ltd. | 4,475,000 7.5% | 4,475,000 (New Position) | View |
| 2020-11-02 4:10 pm Purchase | 13G | INVIVO THERAPEUTICS HLDGS CORP NVIVQ | L1 Capital Global Opportunities Master Fund Ltd. | 2,122,500 8.6% | 2,122,500 (New Position) | View |
| 2020-10-01 4:41 pm Purchase | 13G | TITAN PHARMACEUTICALS INC DEL TTNP | L1 Capital Global Opportunities Master Fund Ltd. | 9,720,000 8.3% | 9,720,000 (New Position) | View |
| 2020-09-30 4:05 pm Purchase | 13G | GEOVAX LABS INC PAR $0.001 GOVX | L1 Capital Global Opportunities Master Fund Ltd. | 383,948 9.9% | 383,948 (New Position) | View |